RASOnD - A comprehensive resource and search tool for RAS superfamily oncogenes from various species
- Umay Kulsum†1,
- Vishwadeep Singh†1,
- Sujata Sharma1,
- A Srinivasan1,
- Tej P Singh1 and
- Punit Kaur1Email author
© Kulsum et al; licensee BioMed Central Ltd. 2011
Received: 1 April 2011
Accepted: 5 July 2011
Published: 5 July 2011
The Ras superfamily plays an important role in the control of cell signalling and division. Mutations in the Ras genes convert them into active oncogenes. The Ras oncogenes form a major thrust of global cancer research as they are involved in the development and progression of tumors. This has resulted in the exponential growth of data on Ras superfamily across different public databases and in literature. However, no dedicated public resource is currently available for data mining and analysis on this family. The present database was developed to facilitate straightforward accession, retrieval and analysis of information available on Ras oncogenes from one particular site.
We have developed the RAS Oncogene Database (RASOnD) as a comprehensive knowledgebase that provides integrated and curated information on a single platform for oncogenes of Ras superfamily. RASOnD encompasses exhaustive genomics and proteomics data existing across diverse publicly accessible databases. This resource presently includes overall 199,046 entries from 101 different species. It provides a search tool to generate information about their nucleotide and amino acid sequences, single nucleotide polymorphisms, chromosome positions, orthologies, motifs, structures, related pathways and associated diseases. We have implemented a number of user-friendly search interfaces and sequence analysis tools. At present the user can (i) browse the data (ii) search any field through a simple or advance search interface and (iii) perform a BLAST search and subsequently CLUSTALW multiple sequence alignment by selecting sequences of Ras oncogenes. The Generic gene browser, GBrowse, JMOL for structural visualization and TREEVIEW for phylograms have been integrated for clear perception of retrieved data. External links to related databases have been included in RASOnD.
This database is a resource and search tool dedicated to Ras oncogenes. It has utility to cancer biologists and cell molecular biologists as it is a ready source for research, identification and elucidation of the role of these oncogenes. The data generated can be used for understanding the relationship between the Ras oncogenes and their association with cancer. The database updated monthly is freely accessible online at http://220.127.116.11/rasond/ and http://www.aiims.edu/RAS.html.
The driving force behind oncogenesis is the transformation of normal cells to uncontrolled cell proliferation and invasion. A number of genes involved in regulating the expression, growth and survival of cells have been identified in events leading to malignant transformation. Ras (RAt Sarcoma) is a major multigene superfamily that has been implicated in approximately 30% of the known human tumors . The predominant cancers involving Ras are associated with lung , colorectal region [3, 4], pancreas  and thyroid . The activation of Ras from a proto-oncogene into an oncogene results from a point mutation in the gene . The Ras oncogenes cause hyperactive cell signalling and consequently contribute to the abnormal growth of the cell. These oncogenes have also been identified in human developmental disorders . The Ras genes are expressed in nearly all tissues, though their expression levels may differ extensively. The most frequently observed Ras genes in human tumors are HRAS (Harvey-Ras), KRAS (Kristen-Ras) and NRAS (neuroblastoma-Ras) which vary in nature and specificity according to the cancer type .
The Ras proto-oncogene encodes a 21 kDa (p21) small monomeric guanine nucleotide-binding protein. The Ras proteins play a central role in the control of normal and transformed cell proliferation. They have the ability to bind both guanosine triphoshate (GTP) and guanosine diphosphate (GDP) and function as a molecular switch in signal transduction by alternating between the inactive GDP-bound state and the active GTP-bound form. The Ras in the active form signals cell growth whereas in the inactive state it cannot initiate these pathways. This binary switch system of the Ras protein is localized to conformational changes in two distinct regions comprising switch I and switch II . The structural changes in the mutated Ras hinder its ability to hydrolyse GTP. The molecular switch gets trapped in the 'switch on' state resulting in increased Ras-GTP levels. The signalling pathway is thus continuously stimulated which leads to oncogenesis . The most commonly observed point mutations in human tumors are at codons 12/13, or 61. Mutations involving residues 59, 63, 116, 117 and 119 have also been implicated in the oncogenic activation by Ras protein .
Ras was the first oncogene to be discovered among the transforming genes of the Harvey and Kirsten murine sarcoma viruses [13, 14]. Since then a large number of Ras genes and proteins have been identified from different species including humans. On the basis of sequence similarity to the founding members , the Ras superfamily has been broadly classified into five main families, Ras , Rho , Arf , Rab  and Ran . An additional family 'Others' has been assigned where their function is not clear. The Ras superfamily has grown and presently consists of over 150 members from humans . Its orthologs have also been identified from nearly 100 other species. This superfamily has been the subject of several general [12, 21–24] and specific reviews emphasizing their role in human and experimental cancer , cell signaling and transformation [26, 27], cell motility , and differential functions in different tumors . Most researchers across the globe have focused mainly on the identification, activation and clinical significance of these oncoproteins. This has led to the accumulation of enormous amount of data across numerous databases and in literature. There is no single database to our knowledge, presently available, where all information is contained on a single platform. This knowledgebase, compiles data from sequence to functional level accessible across diverse databases to enable the user rapid access, retrieval and analysis of information from one location. Thus, RASOnD aims to provide a better understanding of the Ras genes and proteins, their relationship with respect to each other and cancer.
Construction and Content
Overview of the Information content in RASOnD
Ras Families (excluding sub-families)
Nucleotide FASTA Sequences
Protein FASTA Sequences
Single Nucleotide Polymorphisms (SNPs)
User Interface - Simple and Advanced Search
The interfaces in RASOnD are designed to facilitate straightforward navigation and exploitation of tools integrated in the database. The data stored in the RASOnD can be accessed employing a variety of search queries which allow the user to retrieve and analyze the data in a simple way. The users can retrieve information from the database through two user friendly interfaces comprising a 'Simple' and an 'Advanced' search. A search through the database can be performed separately on a particular feature in the simple search as well as simultaneously on multiple fields using the advanced search option. The simple search allows the user to explore the database by selecting a specific individual field from the drop down menu. The user can perform a search by entering the keyword or by selecting the options available in the interface. Various alternatives are present in the simple search.
User Interface - Diseases
The Ras oncogenes have been implicated in a variety of cancers and developmental disorders. The human cancers which have the presence of Ras oncogenes are included as a dropdown menu under the 'Disease' section. The user can choose the disease of interest from this menu. On selection, initially a summary table on human Ras members involved in the preferred disease is returned with a 'Browse' button. The related Ras oncogenes/proteins from other species are also indicated. This page also furnishes a short description of the cancer type.
User Interface - Results
The analysis of the data within the database can be carried out using the tools available in the database. Three tools have been implemented. The users can utilize the genome viewer, 'GBrowse' for browsing associated genes and patterns and profiles of predicted motifs for the selected oncogene. The user can carry out sequence similarity searches from within the database using 'RAS-ON-DBLAST'. The user-defined query nucleotide or protein sequence in FASTA format can be submitted for a local BLAST search against the database to identify homologous sequences. The default or user-defined parameters like e-value cutoff, gap opening, word size or matrix can be modified for such a search. The user can choose sequences returned for direct onward submission to CLUSTALW or download the selected sequences for any other analysis. "CLUSTALW" can be used for the multiple sequence alignment of the selected sequences obtained from the database query. The user can also enter additional sequences of interest. The phylograms generated from CLUSTALW tool can be observed with TreeView.
The home page includes a FAQ page with the purpose of providing basic facts on the Ras superfamily as well as the usage of the entire database. This page also includes a section which is hyperlinked to reviews available in literature. A download option has been provided to obtain data related to nucleotide sequences, protein sequences, single nucleotide polymorphisms and protein structures as separate files. Links to other databases which refer to some Ras superfamily members and latest available literature from PubMed have also been included on the home page.
The main focus of research in molecular cancer is not only the identification of the genes altered in different tumor types but also determination of the pathological role played by them in tumorogenesis. The Ras genes and proteins are particularly very significant as they are activated by point mutations and are the predominant oncogenes in human tumors. The comprehension of different single amino acid substitutions which lead to malignancy is increasingly becoming an important tool to elucidate the mechanisms of oncogenesis. Moreover, the Ras dependent pathways are now being targeted for the development of anti-cancer agents. The objective of this database is to amalgamate information distributed across diverse platforms to a single site. It stores data related to Ras genes and proteins, related polymorphisms, their pathways, associated diseases, motifs and structures. It also contains tools for the examination and analysis of these sequences. It thus, serves as an organized source to both clinicians and basic scientific community for research on Ras superfamily. This resource has been designed to allow the user to explore and extract effortlessly all accessible facts at one common place. RASOnD attempts to bridge the gap between the genomics and system biology and affords inputs and links to all aspects of Ras oncogenes not accessible as a central resource so far. RASOnD is of interest to molecular oncologists and researchers working in the field of cancer as it brings under one roof, data for which otherwise a search would have to be conducted across varied resources. It, therefore, serves as a useful platform for ready reference for identification, determination and comparative analysis of the genes and proteins belonging to the Ras superfamily.
Comparison to other related Databases
There is no similar database to RASOnD, however, there exist a small number of databases which have some reference to the 'Ras' gene/protein "see Additional file 1, Figure S1". These deal with only a few species (unlike the present which includes information on all available species) or present specific rather than generalized and detailed information on the 'Ras' superfamily. Majority have a focus on genomics rather than a proteomics approach unlike RASOnD which provides detailed information on both aspects. These databases include ACTuDB , Catalog of Somatic Mutations in Cancer (COSMIC) database , Dragon database for exploration of ovarian cancer genes (DDOC) , kinase pathway database , mouse genome database , Oncogenomic Database of Hepatocellular carcinoma (OncoDB.HCC) , rat genome database (RGD) , Signal Transduction Classification (STCDB) , Tumor gene family of databases (TGDB)  and Genecards . The rat and mouse genome databases are useful if the focus of search is on these species. COSMIC database contains information on published somatic mutations only in various cancers and refers to just four families of Ras in humans. The DDOC and OncoDB.HCC resources are specific to Ras members implicated in ovarian cancer and hepatocellular carcinoma respectively. The DDOC deals with human Ras members whereas OncoDB.HCC comprises details on rat and mouse besides human members. The ACTuDB contains information on the genomic profiling of tumors only with little emphasis on Ras oncogenes while STCDB has reference to a handful of Ras genes/proteins implicated in signal transduction. The Kinase pathway database refers to only seven species. The GeneCards contains the maximum number of Ras members after RASOnD, however, it also refers to only some species. A link to these databases is available on the home page.
RASOnD is distinct from these published on-line public databases. The main differentiating feature is the inclusion of genomics and proteomics data from all species where Ras members have been identified. Thus, it is the single, specialized largest repository of Ras oncogenes. The purpose of developing RASOnD was to provide a simple solution to clinicians and oncologists to extract information on this gene. Moreover, it affords the alternative of selecting the disease of interest rather than just the Ras oncogene. The initial exploratory sequence analysis from BLAST can further be exploited for multiple sequence alignment with CLUSTALW by a one step selection of the returned sequences. This is a feature unique to the present database. In this manner, the concept of RASOnD is different from other available databases.
The present database focuses mainly on the genes and proteins included in the Ras superfamily, their integration and involvement in different tumors and provides tools for their analysis. We further plan to extend the database with a greater emphasis on the Ras proteins to include their post-translation modifications, interacting partners and inhibitors. Proteins containing the RAS-binding domain will also be incorporated into the database.
The RASOnD knowledgebase is the first attempt to construct an easily accessible and handy platform on the multifaceted large Ras superfamily. RASOnD presents the end-user with all possible details for analysis and retrieval on various aspects of RAS oncogenes in a simple and user friendly manner. Details about various other databases with reference to the Ras have been included. The information in the database can be accessed and investigated by a single query search or by a combination of various queries. Alternatively, the researcher can determine the Ras oncogene involved in a particular cancer type by exercising the dropdown menu under diseases. JMOL, GBrowse and TreeView have been implemented for easy visualization whereas BLAST and CLUSTALW modules have been incorporated for comparative analysis of sequences within the database. The wealth of information available in RASOnD can thus be exploited by both bench side workers and bioinformaticians to carry out a comprehensive analysis on the Ras superfamily. The computational biologists can utilize the compiled data to develop computational prediction tools for novel mutations.
Availability and Requirements
The work was supported by Indian Council of Medical Research in the form of the Bio-Medical Informatics Centre (Grant No. P&I/BIC/1/1/2009). The assistance provided by Mr. Harishankar is also gratefully acknowledged.
- Malumbres A, Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Cancer Rev. 2001, 1: 222-235. 10.1038/35106065.View ArticleGoogle Scholar
- Chiosea S, Shuai Y, Cieply K, Nikiforova MN, Dacic S: EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. Hum Pathol. 2010, 41: 1053-1060. 10.1016/j.humpath.2010.01.008.View ArticlePubMedGoogle Scholar
- Prenen H, Tejpar S, Van Cutsem E: New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res. 2010, 16: 2921-2926. 10.1158/1078-0432.CCR-09-2029.View ArticlePubMedGoogle Scholar
- Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, et al: Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer. 2001, 85: 692-696. 10.1054/bjoc.2001.1964.View ArticlePubMedPubMed CentralGoogle Scholar
- Abou-Alfa GK, Chapman PB, Feilchenfeldt J, Brennan MF, Capanu M, Gansukh B, Jacobs G, Levin A, Neville D, Kelsen DP, O'reilly EM: Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine. Am J Clin Oncol. 2010Google Scholar
- Levy R, Grafi-Cohen M, Kraiem Z, Kloog Y: Galectin-3 Promotes Chronic Activation of K-Ras and Differentiation Block in Malignant Thyroid Carcinomas. Mol Cancer Ther. 2010, 9: 2208-2219. 10.1158/1535-7163.MCT-10-0262.View ArticlePubMedGoogle Scholar
- Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA, Papageorge AG, Scolnick EM, Dhar R, Lowy DR, Chang EH: Mechanism of activation of a human oncogene. Nature. 1982, 300: 143-149. 10.1038/300143a0.View ArticlePubMedGoogle Scholar
- Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, et al: Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A. 2010, 152A: 4-24. 10.1002/ajmg.a.33183.View ArticlePubMedGoogle Scholar
- Lowy DR, Willumsen BM: Function and regulation of ras. Annu Rev Biochem. 1993, 62: 851-891. 10.1146/annurev.bi.62.070193.004223.View ArticlePubMedGoogle Scholar
- Wittinghofer A, Waldmann H: Ras--A Molecular Switch Involved in Tumor Formation. Angewandte Chemie. 2000, 39: 4192-4214. 10.1002/1521-3773(20001201)39:23<4192::AID-ANIE4192>3.0.CO;2-Y.View ArticleGoogle Scholar
- Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG: Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov. 2007, 6: 541-555. 10.1038/nrd2221.View ArticlePubMedGoogle Scholar
- Trahey M, McCormick F: A cytoplasmic protein stimulates normal N-Ras p21 GTPase, but does not affect oncogenic mutants. Science. 1987, 238: 542-545. 10.1126/science.2821624.View ArticlePubMedGoogle Scholar
- Harvey JJ: An unidentified virus which causes the rapid production of tumors in mice. Nature. 1964, 204: 1104-1105.View ArticlePubMedGoogle Scholar
- Kirsten WH, Mayer LA: Morphologic responses to a murine erythroblastosis virus. J Natl Cancer Inst. 1967, 39: 311-335.PubMedGoogle Scholar
- Wennerberg K, Rossman KL, Der CJ: The Ras superfamily at a glance. Journal of Cell Science. 2005, 118: 843-846. 10.1242/jcs.01660.View ArticlePubMedGoogle Scholar
- Reuther GW, Der CJ: The Ras branch of small GTPases:Ras family members don't fall far from the tree. Curr Opin Cell Biol. 2000, 12: 157-165. 10.1016/S0955-0674(99)00071-X.View ArticlePubMedGoogle Scholar
- Sahai E, Marshall CJ: Rho-GTPases and cancer. Nat Rev Cancer. 2002, 2: 133-142. 10.1038/nrc725.View ArticlePubMedGoogle Scholar
- Donaldson JG, Jackson CL: Regulators and effectors of the ARF GTPases. Curr Opin Cell Biol. 2000, 12: 475-482. 10.1016/S0955-0674(00)00119-8.View ArticlePubMedGoogle Scholar
- Samantha L, Schwartz CC, Pylypenko O, Rak A, Wandinger-Ness A: Rab GTPases at a glance. Journal of Cell Science. 2007, 120: 3905-3910. 10.1242/jcs.015909.View ArticleGoogle Scholar
- Kuersten S, Ohno M, Mattaj IW: Nucleocytoplasmic transport: ran, beta and beyond. Trends Cell Biol. 2001, 11: 497-503.S. 10.1016/S0962-8924(01)02144-4.View ArticlePubMedGoogle Scholar
- Macara IG, Lounsbury KM, Richards SA, McKiernan C, Bar-Sagi D: The Ras superfamily of GTPases. FASEB J. 1996, 10: 625-630.PubMedGoogle Scholar
- Goodsell DS: The molecular perspective: the ras oncogene. Oncologist. 1999, 4: 263-264.PubMedGoogle Scholar
- Malumbres M, Barbacid M: RAS oncogenes: the first 30 years. Nature Reviews Cancer. 2003, 3: 459-465. 10.1038/nrc1097.View ArticlePubMedGoogle Scholar
- Barbacid M: ras genes. Ann Rev Biochem. 1987, 56: 779-827. 10.1146/annurev.bi.56.070187.004023.View ArticlePubMedGoogle Scholar
- Roberts PJ, Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007, 26: 3291-3310. 10.1038/sj.onc.1210422.View ArticlePubMedGoogle Scholar
- Malumbres M, Pellicer A: Ras pathways to cell cycle control and cell transformation. Frontiers in Bioscience. 1998, 3: d887-d912.View ArticlePubMedGoogle Scholar
- Mitin N, Rossman KL, Der CJ: Signaling interplay in Ras superfamily function. Curr Biol. 2005, 15: R563-R574. 10.1016/j.cub.2005.07.010.View ArticlePubMedGoogle Scholar
- Oxford G, Theodorescu D: Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Letters. 2003, 189: 117-128. 10.1016/S0304-3835(02)00510-4.View ArticlePubMedGoogle Scholar
- Moon A: Differential functions of Ras for Malignant phenotypic conversion. Arch Pharm Res. 2006, 29: 113-122. 10.1007/BF02974271.View ArticlePubMedGoogle Scholar
- Benson DA, Karsch-Mizrachi l, Lipman DJ, Ostell J, Wheeler DL: GenBank. Nucleic Acids Res. 2008, 36: D25-D30. 10.1093/nar/gkn320.View ArticlePubMedGoogle Scholar
- Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M: KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 2010, 38: D355-D360. 10.1093/nar/gkp896.View ArticlePubMedGoogle Scholar
- Sigrist CJA, Cerutti L, de Castro E, Langendijk-Genevaux PS, Bulliard V, Bairoch A, Hulo N: PROSITE, a protein domain database for functional characterization and annotation. Nucleic Acids Res. 2010, 38: 161-166.View ArticleGoogle Scholar
- UniProt Consortium: The universal protein resource (UniProt). Nucleic Acids Res. 2008, 36: D190-D195. 10.1093/nar/gkn141.View ArticleGoogle Scholar
- Kouranov A, Xie L, de la Cruz J, Chen L, Westbrook J, Bourne PE, Berman HM: The RCSB PDB information portal for structural genomics. Nucleic Acids Res. 2006, 34: D302-D305. 10.1093/nar/gkj120.View ArticlePubMedGoogle Scholar
- Stein LD, Mungall C, Shu S, Caudy M, Mangone M, Day A, Nickerson E, Stajich JE, Harris TW, Arva A, Lewis S: The generic genome browser: a building block for a model organism system database. Genome Res. 2002, 12: 1599-1610. 10.1101/gr.403602.View ArticlePubMedPubMed CentralGoogle Scholar
- Jmol: an open-source Java viewer for chemical structures in 3D. [http://www.jmol.org/]
- Page RDM: TREEVIEW: An application to display phylogenetic trees on personal computers. Computer Applications in the Biosciences. 1996, 12: 357-358.PubMedGoogle Scholar
- Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. J Mol Biol. 1990, 215: 403-410.View ArticlePubMedGoogle Scholar
- Johnson M, Zaretskaya I, Raytselis Y, Merezhuk Y, McGinnis S, Madden TL: NCBI BLAST: a better web interface. Nucleic Acids Res. 2008, W5-W9. 36
- Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG: ClustalW and ClustalX version 2. Bioinformatics. 2007, 23: 2947-2948. 10.1093/bioinformatics/btm404.View ArticlePubMedGoogle Scholar
- Hupé P, La Rosa P, Liva S, Lair S, Servant N, Barillot E: ACTuDB, a new database for the integrated analysis of array-CGH and clinical data for tumors. Oncogene. 2007, 26: 6641-6652. 10.1038/sj.onc.1210488. [http://bioinfo-out.curie.fr/actudb/]View ArticlePubMedGoogle Scholar
- Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA, Stratton MR: The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008, Chapter 10: Unit 10.11, [http://www.sanger.ac.uk/genetics/CGP/cosmic/]Google Scholar
- Kaur M, Radovanovic A, Essack M, Schaefer U, Maqungo M, Kibler T, Schmeier S, Christoffels A, Narasimhan K, Choolani M, Bajic VB: Dragon database for exploration of functional context of genes implicated in ovarian cancer. Nucleic Acids Res. 2009, 37: D820-D823. 10.1093/nar/gkn593. [http://apps.sanbi.ac.za/ddoc/index.php]View ArticlePubMedGoogle Scholar
- Koike A, Kobayashi Y, Takagi T: Kinase pathway database: an integrated protein-kinase and NLP-based protein-interaction resource. Genome Res. 2003, 13: 1231-1243. 10.1101/gr.835903.View ArticlePubMedPubMed CentralGoogle Scholar
- Bult CJ, Kadin JA, Richardson JE, Blake JA, Eppig JT: The Mouse Genome Database: enhancements and updates. Nucleic Acids Res. 2010, 38: D586-D592. 10.1093/nar/gkp880. [http://www.informatics.jax.org/]View ArticlePubMedGoogle Scholar
- Su WH, Chao CC, Yeh SH, Chen DS, Chen PJ, Jou YS: OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. Nucleic Acids Res. 2007, 35: D727-D731. 10.1093/nar/gkl845. [http://oncodb.hcc.ibms.sinica.edu.tw/index.htm]View ArticlePubMedGoogle Scholar
- Twigger S, Lu J, Shimoyama M, Chen D, Pasko D, Long H, Ginster J, Chen CF, Nigam R, Kwitek A, Eppig A, Maltais A, Maglott D, Schuler G, Jacob H, Tonellato PJ: Rat Genome Database (RGD): mapping disease onto the genome. Nucleic Acids Res. 2002, 30: 125-128. 10.1093/nar/30.1.125. [http://rgd.mcw.edu/]View ArticlePubMedPubMed CentralGoogle Scholar
- Chen M, Lin S, Hofestaedt R: STCDB: Signal Transduction Classification Database. Nucleic Acids Res. 2004, 32: D456-D458. 10.1093/nar/gkh079. [http://bibiserv.techfak.uni-bielefeld.de/stcdb/]View ArticlePubMedPubMed CentralGoogle Scholar
- Tumor Gene family of Databases (TGDB). [http://www.tumor-gene.org/TGDB/tgdb.html]
- Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirota-Madi A, Olender T, Golan Y, Stelzer G, Harel A, Lancet D: GeneCards Version 3: the human gene integrator. Database. 2010, baq020, [http://www.genecards.org/]Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.